Galena Biopharma (GALE) : During the past 4 weeks, traders have been relatively bearish on Galena Biopharma (GALE), hence the stock is down -24.14% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -16.26% relative to the S&P 500. The 4-week change in the price of the stock is -25.67% and the stock has fallen -15.82% in the past 1 week.
The stock has recorded a 20-day Moving Average of 19.65% and the 50-Day Moving Average is 24.6%.The 200 Day SMA reached 70.14% Galena Biopharma, Inc. has dropped 85.59% during the last 3-month period . Year-to-Date the stock performance stands at -78.24%.
For the current week, the company shares have a recommendation consensus of Buy. Galena Biopharma (NASDAQ:GALE): stock was range-bound between the intraday low of $0.317 and the intraday high of $0.33 after having opened at $0.33 on Fridays session. The stock finally closed in the red at $0.33, a loss of -3.85%. The stock remained in the red for the whole trading day. The total traded volume was 4,092,274 shares. The stock failed to cross $0.33 in Fridays trading. The stocks closing price on Thursday was $0.3199.
Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.